alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
§ 884.5970 Clitoral engorgement device. ( a ) *Identification.* A clitoral engorgement device is designed to apply a vacuum to the clitoris. It is intended for use in the treatment of female sexual arousal disorder.
( b ) *Classification.* Class II (special controls). The special control is a guidance document entitled: “Guidance for Industry and FDA Reviewers: Class II Special Controls Guidance Document for Clitoral Engorgement Devices.”
[65 FR 47306, Aug. 2, 2000]
```

[Congressional Bills 109th Congress]
[From the U.S. Government Publishing Office]
[S. 110 Introduced in Senate (IS)]

109th CONGRESS
  1st Session
                                 S. 110

            For the relief of Robert Liang and Alice Liang.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            January 24, 2005

Mrs. Feinstein introduced the following bill; which was read twice and 
               referred to the Committee on the Judiciary

_______________________________________________________________________

                                 A BILL

 
            For the relief of Robert Liang and Alice Liang.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. ADJUSTMENT OF STATUS.

    (a) In General.--Notwithstanding any other provision of law or any 
order, for the purposes of the Immigration and Nationality Act (8 
U.S.C. 1101 et seq.), Robert Liang and Alice Liang shall be deemed to 
have been lawfully admitted to, and remained in, the United States, and 
shall be eligible for issuance of an immigrant visa or for adjustment 
of status under section 245 of the Immigration and Nationality Act (8 
U.S.C. 1255).
    (b) Application and Payment of Fees.--Subsection (a) shall apply 
only if the applications for issuance of immigrant visas or the 
applications for adjustment of status are filed with appropriate fees 
within 2 years after the date of enactment of this Act.
    (c) Reduction of Immigrant Visa Numbers.--Upon the granting of 
immigrant visas to Robert Liang and Alice Liang, the Secretary of State 
shall instruct the proper officer to reduce by 2, during the current or 
subsequent fiscal year, the total number of immigrant visas that are 
made available to natives of the country of the aliens' birth under 
section 202(e) or 203(a) of the Immigration and Nationality Act (8 
U.S.C. 1152(e), 1153(a)), as applicable.
                                 <all>
```
# C_2014339EN.01002101.xml

| 29.9.2014 | EN | Official Journal of the European Union | C 339/21 |
| --- | --- | --- | --- |

29.9.2014

EN

Official Journal of the European Union

C 339/21

---

Action brought on 21 July 2014 — Grupo Bimbo v OHIM (Form of round sandwich bread)

(Case T-542/14)

2014/C 339/25

Language of the case: Spanish

Parties

Parties

Applicant: Grupo Bimbo, SAB de CV (Mexico, Mexico) (represented by: N. Fernández Fernández-Pacheco, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Form of order sought

Form of order sought

The applicant claims that the Court should:

| — | annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 19 May 2014 in Case R 1911/2013-4, because it is unlawful and infringes the legal provisions in force concerning the Community trade mark; deliver a judgment in accordance with the claims set out in the application, whether on the basis of the intrinsic distinctiveness of the three-dimensional mark applied for or the distinctiveness acquired by use, upholding the present action and ordering the registration of the application for a three-dimensional Community trade mark No 1 1 7 47  987, for goods in class 30 of the International Classification, on the grounds that it is lawful and admissible; |
| --- | --- |

—

annul the decision of the Fourth Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 19 May 2014 in Case R 1911/2013-4, because it is unlawful and infringes the legal provisions in force concerning the Community trade mark; deliver a judgment in accordance with the claims set out in the application, whether on the basis of the intrinsic distinctiveness of the three-dimensional mark applied for or the distinctiveness acquired by use, upholding the present action and ordering the registration of the application for a three-dimensional Community trade mark No 1 1 7 47  987, for goods in class 30 of the International Classification, on the grounds that it is lawful and admissible;

| — | once the present action has been upheld and the trade mark in question has been registered, order the party opposing that claim to pay the costs of the proceedings and to reimburse the appeal fees paid to OHIM. |
| --- | --- |

—

once the present action has been upheld and the trade mark in question has been registered, order the party opposing that claim to pay the costs of the proceedings and to reimburse the appeal fees paid to OHIM.

Pleas in law and main arguments

Pleas in law and main arguments

Community trade mark: Three-dimensional mark in the form of round sandwich bread for goods in class 30 — Community trade mark application No 1 1 7 47  987

Community trade mark:

Decision of the examiner: Application dismissed

Decision of the examiner:

Decision of the Board of Appeal: Appeal dismissed

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 7(1)(b) of Regulation No 207/2009

Pleas in law:

---
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.3350 *Leptospira* spp. serological reagents. ( a ) *Identification. Leptospira* spp. serological reagents are devices that consist of antigens and antisera used in serological tests to identify antibodies to *Leptospira* spp. in serum or identify *Leptospira* spp. from cultured isolates derived from clinical specimens. Additionally, some of these antisera are conjugated with a fluorescent dye (immunofluorescent reagents) and used to identify *Leptospira* spp. directly from clinical specimens. The identification aids in the diagnosis of leptospirosis caused by bacteria belonging to the genus *Leptospira* and provides epidemiological information on this disease. *Leptospira* infections range from mild fever-producing illnesses to severe liver and kidney involvement producing hemorrhage and dysfunction of these organs.
( b ) *Classification.* Class II (special controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 63 FR 59227, Nov. 3, 1998]
Editorial Note on Part 880
Editorial Note: Nomenclature changes to part 880 appear at 73 FR 35341, June 23, 2008.

§ 880.5210 Intravascular catheter securement device. ( a ) *Identification.* An intravascular catheter securement device is a device with an adhesive backing that is placed over a needle or catheter and is used to keep the hub of the needle or the catheter flat and securely anchored to the skin.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 880.9.
[45 FR 69682, Oct. 21, 1980, as amended at 59 FR 63011, Dec. 7, 1994; 66 FR 38804, July 25, 2001]
## I N T H E C O U R T O F C R I M I N A L A P P E A L S O F T E X A S NOS. WR-82,217-04, WR- 82,217-05 & WR- 82,217-06

EX P ARTE ASHL EY NICOLE RICHARDS, App licant
ON AP P LICATIONS FOR WRITS OF HABEAS CORP US CAUSE NOS. 13857652-B, 1385763-B & 1385765-B IN THE 176 DISTRICT COURT

T H F ROM HARRIS COUNTY
Per curiam . O R D E R P u rs u ant to the provisions of Article 11.07 of the Texas Code of Criminal Procedur e, t h e cler k of th e t ri al co u rt transmitted to this Court these applications for writs of habea s corpus. Ex parte Y oung , 418 S.W .2d 82 4 , 826 (Tex. Crim. App. 1967). Applicant was convicted of three
crue lty to animals charg es and se ntence d to ten year s’ imprisonment in each c ase. Applicant raises three g rounds based on this Court’s rec ent decision deter mining that deadly
wea pon finding s do not apply to non-human victims. Prichard v. State , 533 S.W .3d 315 (Tex. Crim. App. 2017). The habea s court has rec ommended granting relief
. Howeve r, Applicant has challeng ed these convictions befor e and does not demonstrate that Prichard is retroa ctive, making it applicable2

to these case s. Ex parte Oranday-Garcia , 410 S.W .3d 865, 867 (Tex. Crim. App. 2013). There fore , consideration of these writ applications is barr ed by Section 4 of Article 11.07 of the Code of Criminal Procedure . The writ applications are dismiss ed as subse quent. Copies of this order shall be sent to the Texas Depa rtment of Criminal J ustice-Corr ectional Institut ions Division and Pardons and Paroles Division.

Filed: Nove mber 7, 2018 Do not publish
```

[Congressional Bills 118th Congress]
[From the U.S. Government Publishing Office]
[H.R. 7927 Introduced in House (IH)]

<DOC>

118th CONGRESS
  2d Session
                                H. R. 7927

 To require a study on the manner and extent to which the tariff rates 
assessed by the United States on imports are regressive or demonstrate 
                 a gender bias, and for other purposes.

_______________________________________________________________________

                    IN THE HOUSE OF REPRESENTATIVES

                             April 10, 2024

Mrs. Fletcher (for herself, Ms. Pettersen, Mr. Quigley, Mr. Beyer, Ms. 
   Kuster, and Mr. Kilmer) introduced the following bill; which was 
              referred to the Committee on Ways and Means

_______________________________________________________________________

                                 A BILL

 
 To require a study on the manner and extent to which the tariff rates 
assessed by the United States on imports are regressive or demonstrate 
                 a gender bias, and for other purposes.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Pink Tariffs Study Act''.

SEC. 2. STUDY REQUIRED.

    Not later than 1 year after the date of enactment of this Act, the 
Secretary of the Treasury, in coordination with the Commissioner of 
U.S. Customs and Border Protection and in consultation with the United 
States International Trade Commission and the United States Trade 
Representative, shall submit to Congress the results of a study of the 
manner and extent to which the rates of tariffs and the revenues 
collected from tariffs assessed by the United States on articles 
imported into the customs territory of the United States--
            (1) are regressive with respect to the degree to which the 
        burden of such tariffs fall on consumers (such as tariffs that 
        are higher on mass-market consumer goods as compared to 
        analogous luxury goods), including an analysis of the manner 
        and extent to which importation of the applicable goods is 
        foregone to avoid the burden of the tariff;
            (2) demonstrate a bias with respect to the gender of 
        consumer most likely to import such article (such as tariffs 
        that are higher on clothing classifiable as women's clothing as 
        compared to men's clothing);
            (3) a disaggregation of the effects described in paragraphs 
        (1) and (2) with respect to consumers based on gender and 
        household type (single-parent families, double-parent families, 
        other) and income level; and
            (4) such other matters relating to the manner and extent to 
        which the burden of tariffs assessed by the United States on 
        imports falls unequally among certain categories of consumers 
        or households in the United States as the Secretary may 
        determine relevant.
                                 <all>
```
§ 876.5885 Tissue culture media for human ex vivo tissue and cell culture processing applications. ( a ) *Identification.* Tissue culture media for human ex vivo tissue and cell culture processing applications consist of cell and tissue culture media and components that are composed of chemically defined components (e.g., amino acids, vitamins, inorganic salts) that are essential for the ex vivo development, survival, and maintenance of tissues and cells of human origin. The solutions are indicated for use in human ex vivo tissue and cell culture processing applications.
( b ) *Classification.* Class II (special controls): FDA guidance document, “Class II Special Controls Guidance Document: Tissue Culture Media for Human Ex Vivo Processing Applications; Final Guidance for Industry and FDA Reviewers.”
[66 FR 27025, May 16, 2001]
Editorial Note on Part 888
Editorial Note: Nomenclature changes to part 888 appear at 73 FR 35341, June 23, 2008.

§ 888.3045 Resorbable calcium salt bone void filler device. ( a ) *Identification.* A resorbable calcium salt bone void filler device is a resorbable implant intended to fill bony voids or gaps of the extremities, spine, and pelvis that are caused by trauma or surgery and are not intrinsic to the stability of the bony structure.
( b ) *Classification.* Class II (special controls). The special control for this device is the FDA guidance document entitled “Class II Special Controls Guidance: Resorbable Calcium Salt Bone Void Filler Device; Guidance for Industry and FDA.” See § 888.1(e) of this chapter for the availability of this guidance.
[68 FR 32636, June 2, 2003]
# C_2014339EN.01002702.xml

| 29.9.2014 | EN | Official Journal of the European Union | C 339/27 |
| --- | --- | --- | --- |

29.9.2014

EN

Official Journal of the European Union

C 339/27

---

Action brought on 14 August 2014 — Industrias Tomás Morcillo v OHIM — Aucar Trailer (Polycart A Whole Cart Full of Benefits)

(Case T-613/14)

2014/C 339/33

Language in which the application was lodged: Spanish

Parties

Parties

Applicant: Industrias Tomás Morcillo, SL (Albuixech, Spain) (represented by: A. Sanz-Bermell y Martínez, lawyer)

Applicant:

Defendant: Office for Harmonisation in the Internal Market (Trade Marks and Designs)

Defendant:

Other party to the proceedings before the Board of Appeal: Aucar Trailer, SL (Premia de Mar, Spain)

Other party to the proceedings before the Board of Appeal:

Form of order sought

Form of order sought

The applicant claims that the General Court should:

| — | annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 7 May 2014 in Case R 1735/2012-1 and, accordingly, dismiss the opposition brought by Aucar Trailer S.L., allowing the grant of Community trade mark No 9 6 90  314‘Polycart A Whole Cart Full of Benefits’ in respect of the goods applied for pursuant to the limitation of 16 November 2012, and dismissing the opposition brought against the same; |
| --- | --- |

—

annul the decision of the First Board of Appeal of the Office for Harmonisation in the Internal Market (Trade Marks and Designs) of 7 May 2014 in Case R 1735/2012-1 and, accordingly, dismiss the opposition brought by Aucar Trailer S.L., allowing the grant of Community trade mark No 9 6 90  314‘Polycart A Whole Cart Full of Benefits’ in respect of the goods applied for pursuant to the limitation of 16 November 2012, and dismissing the opposition brought against the same;

| — | order the defendant to pay the costs. |
| --- | --- |

—

order the defendant to pay the costs.

Pleas in law and main arguments

Pleas in law and main arguments

Applicant for a Community trade mark: The applicant

Applicant for a Community trade mark:

Community trade mark concerned: Figurative mark with word elements ‘Polycart A Whole Cart Full of Benefits’ for goods in Classes 12, 17 and 20 — Community trade mark application No 9 6 90  314

Community trade mark concerned:

Proprietor of the mark or sign cited in the opposition proceedings: The other party to the proceedings before the Board of Appeal

Proprietor of the mark or sign cited in the opposition proceedings:

Mark or sign cited in opposition: Figurative mark with word element ‘POLICAR’ for goods and services in Classes 12, 35 and 37

Mark or sign cited in opposition:

Decision of the Opposition Division: Opposition upheld

Decision of the Opposition Division:

Decision of the Board of Appeal: Appeal dismissed

Decision of the Board of Appeal:

Pleas in law: Infringement of Article 8 of Regulation No 207/2009

Pleas in law:

---
PROMOTION LETTER OF JACK LITTLEY

                                   MEMORANDUM

TO:       John Littley III

FROM:     John Spotila

DATE:     February 20, 2003

SUBJECT:  Promotion to Senior Vice President

--------------------------------------------------------------------------------

Dendy and I are very pleased to confirm your promotion to Senior Vice President,
Program and Information Services effective January 7, 2003. In this capacity,
you continue to report to me. In line with your new responsibilities, we have
decided to increase your base salary to $190,000 per year effective
retroactively to the effective date. With your incentive compensation plan of
$100,000, your new annual target compensation is $290,000 ($190,000 base,
$100,000 incentive).

We are pleased to advise you that the Board has approved the issuance to you of
new options for an additional 30,000 shares of GTSI Common Stock. The Grant Date
for these options is January 28, 2003. Your exercise price will be equal to the
closing price of the Company's Common Stock on the Grant Date. Your options will
vest and be exercisable, cumulatively, in four equal annual installments with
the first installment vesting on the first anniversary of the Grant Date. They
will be subject to the terms and provisions of a Stock Option Agreement which we
will be providing you shortly. Your options will expire, to the extent not
previously exercised, upon the earlier of ten years from the date of initial
vesting or one month after you cease to be a GTSI employee.

Bridget Atkinson will follow up with you as needed if you have any questions
about your new compensation. As always, we ask that you keep confidential all
matters associated with your compensation. Please sign below on the enclosed
copy of this memo to signify your acceptance of this new role within GTSI and
return it to Bridget as soon as possible.

Jack, this recognizes your excellent contributions to GTSI in the past and your
continued commitment to our success. You have our sincerest congratulations and
best wishes.

Acknowledged & Accepted:

John Littley III


                                       89
Editorial Note on Part 866
Editorial Note: Nomenclature changes to part 866 appear at 73 FR 35341, June 23, 2008.

§ 866.2170 Automated colony counter. ( a ) *Identification.* An automated colony counter is a mechanical device intended for medical purposes to determine the number of bacterial colonies present on a bacteriological culture medium contained in a petri plate. The number of colonies counted is used in the diagnosis of disease as a measure of the degree of bacterial infection.
( b ) *Classification.* Class I (general controls). The device is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 866.9.
[47 FR 50823, Nov. 9, 1982, as amended at 54 FR 25045, June 12, 1989; 66 FR 38790, July 25, 2001]
Editorial Note on Part 870
Editorial Note: Nomenclature changes to part 870 appear at 73 FR 35341, June 23, 2008.

§ 870.2700 Oximeter. ( a ) *Identification.* An oximeter is a device used to transmit radiation at a known wavelength(s) through blood and to measure the blood oxygen saturation based on the amount of reflected or scattered radiation. It may be used alone or in conjunction with a fiberoptic oximeter catheter.
( b ) *Classification.* Class II (performance standards).
[No. 21195-5-II.

Division Two.

December 19, 1997.]

#### The State of Washington, *Respondent,*v. Terrill Nathan Shirk, *Appellant.*

Appeal from a judgment of the Superior Court for Lewis County, No. 96-1-00240-7, H. John Hall, J., entered September 27, 1996. *Reversed*by unpublished opinion per Hunt, J., concurred in by Bridgewater, A.C.J., and Armstrong, J.
§ 900.22 Standards for certification agencies. The certification agency shall accept the following responsibilities in order to ensure quality mammography at the facilities it certifies and shall perform these responsibilities in a manner that ensures the integrity and impartiality of the certification agency's actions: ( a ) *Conflict of interest.* The certification agency shall establish and implement measures that FDA has approved in accordance with § 900.21(b) to reduce the possibility of conflict of interest or facility bias on the part of individuals acting on the certification agency's behalf.
( b ) *Certification and inspection responsibilities.* Mammography facilities shall be certified and inspected in accordance with statutory and regulatory requirements that are at least as stringent as those of MQSA and this part.
( c ) *Compliance with quality standards.* The scope, timeliness, disposition, and technical accuracy of completed inspections and related enforcement activities shall ensure compliance with facility quality standards required under § 900.12.
( d ) *Enforcement actions.* ( 1 ) There shall be appropriate criteria and processes for the suspension and revocation of certificates.
( 2 ) There shall be prompt investigation of and appropriate enforcement action for facilities performing mammography without certificates.
( e ) *Appeals.* There shall be processes for facilities to appeal inspection findings, enforcement actions, and adverse certification decision or adverse accreditation decisions after exhausting appeals to the accreditation body.
( f ) *Additional mammography review.* There shall be a process for the certification agency to request additional mammography review from accreditation bodies for issues related to mammography image quality and clinical practice. The certification agency should request additional mammography review only when it believes that mammography quality at a facility has been compromised and may present a serious risk to human health.
( g ) *Patient notification.* There shall be processes for the certification agency to conduct, or cause to be conducted, patient notifications should the certification agency determine that mammography quality has been compromised to such an extent that it may present a serious risk to human health.
( h ) *Electronic data transmission.* There shall be processes to ensure the timeliness and accuracy of electronic transmission of inspection data and facility certification status information in a format and timeframe determined by FDA.
( i ) *Changes to standards.* A certification agency shall obtain FDA authorization for any changes it proposes to make in any standard that FDA has previously accepted under § 900.21 before requiring facilities to comply with the changes as a condition of obtaining or maintaining certification.